Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 96

Similar articles for PubMed (Select 9176068)

1.

Tumour necrosis factor and Crohn's disease.

Van Deventer SJ.

Gut. 1997 Apr;40(4):443-8. Review. No abstract available.

2.

Antibodies to tumour necrosis factor alpha as treatment for Crohn's disease.

Bell S, Kamm MA.

Lancet. 2000 Mar 11;355(9207):858-60. No abstract available.

PMID:
10752696
3.

Tumour-necrosis-factor antibody treatment in Crohn's disease.

Derkx B, Taminiau J, Radema S, Stronkhorst A, Wortel C, Tytgat G, van Deventer S.

Lancet. 1993 Jul 17;342(8864):173-4. No abstract available.

PMID:
8101267
4.

Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis.

Baert FJ, D'Haens GR, Peeters M, Hiele MI, Schaible TF, Shealy D, Geboes K, Rutgeerts PJ.

Gastroenterology. 1999 Jan;116(1):22-8.

PMID:
9869598
5.

Anti-TNF alpha therapy is useful in rheumatoid arthritis and Crohn's disease: analysis of the mechanism of action predicts utility in other diseases.

Feldman M, Taylor P, Paleolog E, Brennan FM, Maini RN.

Transplant Proc. 1998 Dec;30(8):4126-7. Review. No abstract available.

PMID:
9865320
6.

Crohn's disease, TNF-alpha, and the leaky gut. The chicken or the egg?

Hollander D.

Am J Gastroenterol. 2002 Aug;97(8):1867-8. No abstract available.

PMID:
12190145
7.

Tumor necrosis factor-alpha monoclonal antibodies for Crohn's disease: tipping the balance.

Danese S, Pagano N, Angelucci E, Stefanelli T, Repici A, Omodei P, Daperno M, Malesci A.

Curr Med Chem. 2007;14(14):1489-97. Review.

PMID:
17584058
8.

Strategies targeting tumor necrosis factor in Crohn's disease.

Sandborn WJ.

Acta Gastroenterol Belg. 2001 Apr-Jun;64(2):170-2. Review.

PMID:
11475128
9.

Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease.

Van den Brande JM, Braat H, van den Brink GR, Versteeg HH, Bauer CA, Hoedemaeker I, van Montfrans C, Hommes DW, Peppelenbosch MP, van Deventer SJ.

Gastroenterology. 2003 Jun;124(7):1774-85.

PMID:
12806611
10.

Anti-TNF antibody treatment of Crohn's disease.

van Deventer SJ.

Ann Rheum Dis. 1999 Nov;58 Suppl 1:I114-20. Review. No abstract available.

11.
12.

Chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease.

Hawkey CJ, Stack WA.

N Engl J Med. 1998 Jan 29;338(5):333-4. No abstract available.

PMID:
9446034
13.

Pharmacogenomics of response to anti-tumor necrosis factor therapy in patients with Crohn's disease.

Shetty A, Forbes A.

Am J Pharmacogenomics. 2002;2(4):215-21. Review.

PMID:
12421092
14.

Anti tumour necrosis-alpha therapy increases the number of FOXP3 regulatory T cells in children affected by Crohn's disease.

Ricciardelli I, Lindley KJ, Londei M, Quaratino S.

Immunology. 2008 Oct;125(2):178-83. doi: 10.1111/j.1365-2567.2008.02839.x. Epub 2008 Apr 16.

15.

Antibody to tumor necrosis factor in the treatment of Crohn's disease.

Stricker T, Braegger CP.

J Pediatr Gastroenterol Nutr. 1998 Sep;27(3):369-70. No abstract available.

PMID:
9740217
16.

A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease.

Plevy SE, Landers CJ, Prehn J, Carramanzana NM, Deem RL, Shealy D, Targan SR.

J Immunol. 1997 Dec 15;159(12):6276-82.

PMID:
9550432
17.

Antibodies to tumor necrosis factor-alpha in the treatment of Crohn's disease.

Brown SJ, Abreu MT.

Curr Opin Drug Discov Devel. 2005 Mar;8(2):160-8. Review.

PMID:
15782540
18.

p38 mitogen-activated protein kinase is activated and linked to TNF-alpha signaling in inflammatory bowel disease.

Waetzig GH, Seegert D, Rosenstiel P, Nikolaus S, Schreiber S.

J Immunol. 2002 May 15;168(10):5342-51.

19.

CD4 antibody treatment in Crohn's disease.

Stronkhorst A, Tytgat GN, van Deventer SJ.

Scand J Gastroenterol Suppl. 1992;194:61-5.

PMID:
1298050
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk